Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
暂无分享,去创建一个
Y. Cheng | X. Liang | Chunyang Li | Lifen Gao | Chunhong Ma | Y. Liu | Y. Xu | Y Xu | C. Ma | Z. Wang | X. Du | C. Li | J. Peng | L. Gao | Y Liu | Y Cheng | Z Wang | X Du | C Li | J Peng | L Gao | X Liang | C Ma | Y. Cheng | Y. Cheng | Xiuming Liang | Yong Xu | Xianhong Du | Jiali Peng | Y. Cheng | Xiuming Liang | Yang Liu | Zhiyong Wang
[1] H. Dockrell,et al. PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment , 2015, PloS one.
[2] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[3] A. Pera,et al. Immunosenescence: limitations of natural killer cell-based cancer immunotherapy , 2017, Cancer Immunology, Immunotherapy.
[4] W. Pan,et al. Monocyte/macrophage‐elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions , 2013, Hepatology.
[5] A. Fauci,et al. The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands , 2008, The Journal of Immunology.
[6] W. Mao,et al. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma , 2016, Oncotarget.
[7] Xiang Gao,et al. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. , 2013, The Journal of clinical investigation.
[8] C. Macedo,et al. Decreased NKp46 and NKG2D and elevated PD‐1 are associated with altered NK‐cell function in pediatric transplant patients with PTLD , 2012, European journal of immunology.
[9] Yan Chen,et al. Human fused NKG2D–IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells , 2015, Cellular and Molecular Immunology.
[10] Jingting Jiang,et al. PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor , 2016, Clinical Cancer Research.
[11] Jiri Polivka,et al. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, Pharmacology & therapeutics.
[12] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[13] R. Issels,et al. Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients , 2016, Oncoimmunology.
[14] D. Olive,et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization , 2017, The Journal of allergy and clinical immunology.
[15] A. Kamphorst,et al. Manipulating the PD-1 pathway to improve immunity. , 2013, Current opinion in immunology.
[16] R. Koup,et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection , 2006, The Journal of experimental medicine.
[17] A. Lanfranco,et al. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.
[18] Jun Du,et al. Involvement of Indoleamine 2,3-Dioxygenase in Impairing Tumor-Infiltrating CD8+ T-Cell Functions in Esophageal Squamous Cell Carcinoma , 2011, Clinical & developmental immunology.
[19] W. Chua,et al. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. , 2016, Clinical colorectal cancer.
[20] Abdus S. Wahed,et al. Cutting Edge: Programmed Death-1 Expression Is Increased on Immunocytes in Chronic Hepatitis C Virus and Predicts Failure of Response to Antiviral Therapy: Race-Dependent Differences12 , 2008, The Journal of Immunology.
[21] J. Riley. PD‐1 signaling in primary T cells , 2009, Immunological reviews.
[22] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[23] M. Caligiuri,et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.
[24] G. Dranoff,et al. Dual roles for immunity in gastrointestinal cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[26] J. Berzofsky,et al. Lack of the programmed death‐1 receptor renders host susceptible to enteric microbial infection through impairing the production of the mucosal natural killer cell effector molecules , 2016, Journal of leukocyte biology.
[27] A. Mackensen,et al. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.
[28] Eric Vivier,et al. Functions of natural killer cells , 2008, Nature Immunology.
[29] G. Giannelli,et al. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment , 2014, Gut.
[30] Adam Coleman,et al. PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection. , 2012, Viral immunology.
[31] Hongxin Ma,et al. Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages , 2015, Gut.
[32] Seung-Hwan Lee,et al. IL-15–PI3K–AKT–mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells , 2015, Front. Immunol..
[33] Camille Guillerey,et al. Targeting natural killer cells in cancer immunotherapy , 2016, Nature Immunology.
[34] H. Fujii,et al. NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma. , 2010, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[35] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[36] Adam J. Bass,et al. The Tumor Microenvironment in Esophageal Cancer , 2016, Oncogene.
[37] Xinxiang Li,et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer , 2016, Molecular Cancer.
[38] Y. Mohri,et al. Role of inflammation and tumor microenvironment in the development of gastrointestinal cancers: what induced pluripotent stem cells can do? , 2015, Current Stem Cell Research & Therapy.
[39] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[40] Yuzhang Wu,et al. Programmed Death (PD)-1-Deficient Mice Are Extremely Sensitive to Murine Hepatitis Virus Strain-3 (MHV-3) Infection , 2011, PLoS pathogens.
[41] J. Wargo,et al. Monitoring immune responses in the tumor microenvironment. , 2016, Current opinion in immunology.
[42] T. Osaki,et al. Increased PD‐1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer , 2013, Journal of surgical oncology.
[43] Song Han,et al. The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells , 2015, PloS one.
[44] D. Olive,et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma , 2016, Oncotarget.
[45] K. Patel,et al. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability , 2016, The American journal of surgical pathology.
[46] Laura F. Dagley,et al. CIS is a potent checkpoint in NK cell–mediated tumor immunity , 2016, Nature Immunology.
[47] X. Lu,et al. Tim‐3/galectin‐9 signaling pathway mediates T‐cell dysfunction and predicts poor prognosis in patients with hepatitis B virus‐associated hepatocellular carcinoma , 2012, Hepatology.
[48] J. Larrubia,et al. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. , 2016, World journal of gastroenterology.